Changes in the Board of Directors of Bellevue Group

Barbara Angehrn Pavik has held a number of executive functions across the international healthcare industry for more than 20 years, most recently as Chief Business Officer and a member of the Executive Board at Vifor Pharma Group. Prior to the four years she spent at Vifor Pharma Group, Barbara Angehrn Pavik was the founder and CEO of Stepstone Pharma and she also held executive positions at Exelixis Pharmaceuticals International, San Francisco, Onyx Pharmaceuticals International, Zug, and Amgen International, Zug. Barbara Angehrn Pavik has been on the Board of Directors of Medmix since 2022.

As announced earlier, Bellevue’s long-serving director Daniel Sigg has decided not to stand for re-election at the 2023 Annual General Meeting. Daniel Sigg helped shape Bellevue Group’s strategy for the past 16 years.

Veit de Maddalena, Chairman of the Board of Directors, on the Board changes: «We're very pleased that Barbara Angehrn Pavik will serve on Bellevue’s Board of Directors and further strengthen its expertise. With her many years of international experience, she can give our Group, a leading healthcare investment specialist, additional valuable inputs in the years to come. I thank Daniel Sigg for his competent services over the years. He left a distinct mark on Bellevue's corporate development and strategic repositioning. We wish him all the best for the future.»

 Financial calendar 2023:
February 28, 2023:          Presentation of annual results 2022

Media Relations
Jürg Stähelin, IRF
Telephone: +41 43 244 81 51, staehelin@irf-reputation.ch

Investor Relations
Michael Hutter, CFO Bellevue Group
Telephone: +41 44 267 67 00, mhu@bellevue.ch